1. Home
  2. CDT vs AQMS Comparison

CDT vs AQMS Comparison

Compare CDT & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • AQMS
  • Stock Information
  • Founded
  • CDT 2019
  • AQMS 2014
  • Country
  • CDT United States
  • AQMS United States
  • Employees
  • CDT N/A
  • AQMS N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • AQMS Metal Fabrications
  • Sector
  • CDT Health Care
  • AQMS Industrials
  • Exchange
  • CDT Nasdaq
  • AQMS Nasdaq
  • Market Cap
  • CDT 5.2M
  • AQMS 5.2M
  • IPO Year
  • CDT N/A
  • AQMS 2015
  • Fundamental
  • Price
  • CDT $1.64
  • AQMS $3.89
  • Analyst Decision
  • CDT
  • AQMS Buy
  • Analyst Count
  • CDT 0
  • AQMS 1
  • Target Price
  • CDT N/A
  • AQMS $30.00
  • AVG Volume (30 Days)
  • CDT 95.0K
  • AQMS 65.5K
  • Earning Date
  • CDT 08-26-2025
  • AQMS 08-13-2025
  • Dividend Yield
  • CDT N/A
  • AQMS N/A
  • EPS Growth
  • CDT N/A
  • AQMS N/A
  • EPS
  • CDT N/A
  • AQMS N/A
  • Revenue
  • CDT N/A
  • AQMS N/A
  • Revenue This Year
  • CDT N/A
  • AQMS N/A
  • Revenue Next Year
  • CDT N/A
  • AQMS $550.00
  • P/E Ratio
  • CDT N/A
  • AQMS N/A
  • Revenue Growth
  • CDT N/A
  • AQMS N/A
  • 52 Week Low
  • CDT $1.61
  • AQMS $3.40
  • 52 Week High
  • CDT $274.80
  • AQMS $54.00
  • Technical
  • Relative Strength Index (RSI)
  • CDT 29.41
  • AQMS 37.51
  • Support Level
  • CDT $1.66
  • AQMS $3.58
  • Resistance Level
  • CDT $1.85
  • AQMS $4.54
  • Average True Range (ATR)
  • CDT 0.11
  • AQMS 0.46
  • MACD
  • CDT 0.03
  • AQMS 0.07
  • Stochastic Oscillator
  • CDT 8.36
  • AQMS 26.63

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About AQMS Aqua Metals Inc.

Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.

Share on Social Networks: